Neal Dunlap

Dr. Neal Dunlap


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2014 in Head & Neck
Verified
Journal Article
Closed access
PDF file
ABAashish D. Bhatt
Aashish D. Bhatt
NGNicole Goodwin
Nicole Goodwin
ECElizabeth Cash
Elizabeth Cash
GBGeetika Bhatt
Geetika Bhatt
CSCraig L. Silverman
Craig L. Silverman
NDNeal Dunlap
Neal Dunlap

1 January 2016 in The Journal of Community and Supportive Oncology
Verified
Journal Article
Closed access
TFTeresa Finnegan
Teresa Finnegan
JSJoseph Shaughnessy
Joseph Shaughnessy
CPCesar Perez
Cesar Perez
RRRebecca Redman
Rebecca Redman
CSCraig Silverman
Craig Silverman
NDNeal Dunlap
Neal Dunlap
Effective palliation in patients with locally advanced head and neck cancer is important. Cyclical hypofractionated radiotherapy (Quad Shot) is a short-course palliative regimen with good patient compliance, low rates of acute toxicity, and delayed late fibrosis. To review use of the Quad Shot technique at our institution in order to quantify the palliative response in locally advanced head and neck cancer. The medical records of 70 patients with head and neck squamous cell carcinoma who had been treated with the Quad Shot technique were analyzed retrospectively (36 had been treated with intensity-modulated radiation therapy and 34 with 3-D conformal radiotherapy). They had received cyclical hypofractionated radiotherapy administrated as 14.8 Gy in 4 fractions over 2 days, twice daily, repeated every 3 weeks for a total of 3 cycles. The total prescribed dose was 44.4 Gy. Primary endpoints were improvement in pain using a verbal numeric pain rating scale (range 1-10, 10 being severe pain) and dysphagia using the Food Intake Level Scale, and the secondary endpoints included overall survival (OS), local regional recurrence-free survival (LRRFS), progression-free survival (PFS) and time to progression. Pain response occurred in 61% of the patients. The mean pain scores decreased significantly from pre to post treatment (5.81 to 2.55, 𝑃 = .009). The mean initial dysphagia score improved from 2.20 to 4.77 55 (𝑃 = .045). 26% of patients developed mucositis (≤ grade 2), with 9% developing grade 3-level mucositis. 12 patients had tumor recurrence. The estimated 1-year PFS was 20.7%. The median survival was 3.85 months with an estimated 1-year OS of 22.6%. Pain response (hazard ratio [HR], 2.69; 95% confidence index [CI], I.552-1.77) and completion of all 3 cycles (HR, 1.71; 95% CI, 1.003-2.907) were predictive for improved OS. This study is a retrospective analysis. Quad Shot is an appropriate palliative regimen for locally advanced head and neck cancer.

1 January 2019 in Oral Oncology
Verified
Journal Article
Closed access
MMMichael E. May
Michael E. May
ECElizabeth D. Cash
Elizabeth D. Cash
CSCraig L. Silverman
Craig L. Silverman
RRRebecca A. Redman
Rebecca A. Redman
CPCesar A. Perez
Cesar A. Perez
NDNeal Dunlap
Neal Dunlap

1 July 2015 in Practical Radiation Oncology
Verified
Journal Article
Closed access
JJJoshua James
Joshua James
CSChristine Swanson
Christine Swanson
BLBart Lynch
Bart Lynch
BWBrian Wang
Brian Wang
NDNeal Dunlap
Neal Dunlap

1 May 2016 in The Journal of Community and Supportive Oncology
Verified
Journal Article
Closed access
MBMatthew Bertke
Matthew Bertke
JSJoseph Shaughnessy
Joseph Shaughnessy
MFMatthew Forsthoefel
Matthew Forsthoefel
LCLiz Cash
Liz Cash
CSCraig Silverman
Craig Silverman
NDNeal Dunlap
Neal Dunlap
The influence of HPV in postoperative HNSCC seems limited compared with traditional risk factors such as ECE, LVSI, and PNI. De-escalation of postoperative treatment based on HPV status alone should be approached with caution.

22 November 2014 in Journal of Radiation Oncology
Verified
Journal Article
Closed access
PDF file
RNRam Narayan
Ram Narayan
JSJoseph Shaughnessy
Joseph Shaughnessy
CSCraig Silverman
Craig Silverman
JBJeffrey Bumpous
Jeffrey Bumpous
KPKevin Potts
Kevin Potts
NDNeal Dunlap
Neal Dunlap